 |
|
|
|
 |
|
|
| Article 1 to 10 out of 25 concerning Geron Corporation
|
-
Pharmexa again prevails against Geron in patent appeal
(09/04/2007)
In May 2004 the US biotech company Geron filed an opposition against Pharmexa's issued European patent (EP1093381) covering the telomerase vaccine GV1001. In 2005, the Opposition Division of the European Patent Office refused to grant Geron's ...
-
Studies confirm proof-of-principle for Geron's Human Embryonic Stem Cell (HESC) derived hepatocytes
(04/23/2007)
Geron Corporation announced that it has developed standardized hepatocytes from human embryonic stem cells (hESCs) that can model human hepatic drug metabolism.Published in Cloning and Stem Cells (Vol. 9, No. 1, 51-62), a paper written by Geron's ...
-
GTC Biotherapeutics obtains license to nuclear transfer patents
(04/12/2007)
GTC Biotherapeutics, Inc. announced that it has been granted a non-exclusive worldwide license from Start Licensing, Inc., a joint venture between Geron Corporation and Exeter Life Sciences, Inc., for the patents and patent applications developed by ...
-
Studies show Geron's stem cell therapeutic for spinal cord injury produces nerve growth factors
(01/19/2007)
Geron Corporation reported that studies show GRNOPC1, the company's human embryonic stem cell (hESC)-based oligodendroglial progenitor therapeutic, produces multiple nerve growth factors, proteins that stimulate the survival and regeneration of ...
-
Geron presents early clinical trial data for its telomerase inhibitor cancer drug
(11/14/2006)
Geron Corporation announced the first clinical trial data for its telomerase inhibitor cancer drug, GRN163L. Presented by Laurence Elias, M.D., Geron's vice president, oncology clinical development, the data demonstrate the safety, tolerability and ...
-
Geron licenses antigen targeting patents for cancer research vaccine program from Immunomic Therapeutics
(11/07/2006)
Geron Corporation and Immunomic Therapeutics Inc. (ITI) announced a patent license agreement under which Geron will receive exclusive rights to the LAMP antigen targeting sequence for use in cancer vaccines.Geron's therapeutic cancer vaccine, ...
-
Geron appoints Alan Colowick as president, oncology
(10/18/2006)
Geron Corporation announced the appointment of Alan B. Colowick, M.D., M.P.H., as president, oncology. In this newly created position, Dr. Colowick, 44, will manage the operational and strategic activities of the company's oncology programs. He will ...
-
Geron and University of Edinburgh collaborate on development of cell types derived from human embryonic stell cells
(08/09/2006)
Geron Corporation and the University of Edinburgh have entered into a collaboration to conduct preclinical safety and efficacy studies with three cell types derived from human embryonic stem cells (hESCs). The cell types are hepatocytes for the ...
-
Invitrogen Licenses Geron Intellectual Property for Development of Research Tools
(07/04/2006)
Invitrogen Corporation and Geron Corporation announced that Invitrogen has licensed Geron intellectual property related to the growth of human embryonic stem cells (hESCs). The agreement provides Invitrogen with a non-exclusive license under Geron's ...
-
Pharmexa prevails in opposition against Geron's European patent
(06/19/2006)
Pharmexa has filed an opposition against the US biotech company Geron's European patent (EP841396) to the European Patent Office (EPO) and has requested an invalidation of three claims in the patent related to peptide vaccines against telomerase. In ...
|
|
|
|
|
Top
